Phenotype ~ Triple Negative Breast Cancer
~ Genetics of Breast & Ovarian Cancer

Characterization of aspects of TNBC (including for non-BRCA1/2 carriers, and for non-specified mutation status) beyond molecular and treatment concerns. See "Treatment ~ Triple Negative Breast Cancer" for the latter.

List was last updated on Nov 19, 2019 @ 8:34 pm.


    • Triple negative breast cancer: microRNA expression profile and novel discriminators according to BRCA1 status.
    • Abdel-Sater F, Najar M, Fayyad-Kazan H.
    • J Cell Physiol. 2019 Nov 17. doi: 10.1002/jcp.29398. [Epub ahead of print]
    • The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer.
    • Figlioli G, Bogliolo M, Catucci I, Caleca L, Lasheras SV, Pujol R, Kiiski JI, Muranen TA, Barnes DR, Dennis J, Michailidou K, Bolla MK, Leslie G, Aalfs CM; ABCTB Investigators, Adank MA, Adlard J, Agata S, Cadoo K, Agnarsson BA, Ahearn T, Aittomäki K, Ambrosone CB, Andrews L, Anton-Culver H, Antonenkova NN, Arndt V, Arnold N, Aronson KJ, Arun BK, Asseryanis E, Auber B, Auvinen P, Azzollini J, Balmaña J, Barkardottir RB, Barrowdale D, Barwell J, Beane Freeman LE, Beauparlant CJ, Beckmann MW, Behrens S, Benitez J, Berger R, Bermisheva M, Blanco AM, Blomqvist C, Bogdanova NV, Bojesen A, Bojesen SE, Bonanni B, Borg A, Brady AF, Brauch H, Brenner H, Brüning T, Burwinkel B, Buys SS, Caldés T, Caliebe A, Caligo MA, Campa D, Campbell IG, Canzian F, Castelao JE, Chang-Claude J, Chanock SJ, Claes KBM, Clarke CL, Collavoli A, Conner TA, Cox DG, Cybulski C, Czene K, Daly MB, de la Hoya M, Devilee P, Diez O, Ding YC, Dite GS, Ditsch N, Domchek SM, Dorfling CM, Dos-Santos-Silva I, Durda K, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Ellberg C, Eriksson M, Evans DG, Fasching PA, Figueroa J, Flyger H, Foulkes WD, Friebel TM, Friedman E, Gabrielson M, Gaddam P, Gago-Dominguez M, Gao C, Gapstur SM, Garber J, García-Closas M, García-Sáenz JA, Gaudet MM, Gayther SA; GEMO Study Collaborators, Giles GG, Glendon G, Godwin AK, Goldberg MS, Goldgar DE, Guénel P, Gutierrez-Barrera AM, Haeberle L, Haiman CA, Håkansson N, Hall P, Hamann U, Harrington PA, Hein A, Heyworth J, Hillemanns P, Hollestelle A, Hopper JL, Hosgood HD 3rd, Howell A, Hu C, Hulick PJ, Hunter DJ, Imyanitov EN; KConFab, Isaacs C, Jakimovska M, Jakubowska A, James P, Janavicius R, Janni W, John EM, Jones ME, Jung A, Kaaks R, Karlan BY, Khusnutdinova E, Kitahara CM, Konstantopoulou I, Koutros S, Kraft P, Lambrechts D, Lazaro C, Le Marchand L, Lester J, Lesueur F, Lilyquist J, Loud JT, Lu KH, Luben RN, Lubinski J, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Martens JWM, Maurer T, Mavroudis D, Mebirouk N, Meindl A, Menon U, Miller A, Montagna M, Nathanson KL, Neuhausen SL, Newman WG, Nguyen-Dumont T, Nielsen FC, Nielsen S, Nikitina-Zake L, Offit K, Olah E, Olopade OI, Olshan AF, Olson JE, Olsson H, Osorio A, Ottini L, Peissel B, Peixoto A, Peto J, Plaseska-Karanfilska D, Pocza T, Presneau N, Pujana MA, Punie K, Rack B, Rantala J, Rashid MU, Rau-Murthy R, Rennert G, Lejbkowicz F, Rhenius V, Romero A, Rookus MA, Ross EA, Rossing M, Rudaitis V, Ruebner M, Saloustros E, Sanden K, Santamariña M, Scheuner MT, Schmutzler RK, Schneider M, Scott C, Senter L, Shah M, Sharma P, Shu XO, Simard J, Singer CF, Sohn C, Soucy P, Southey MC, Spinelli JJ, Steele L, Stoppa-Lyonnet D, Tapper WJ, Teixeira MR, Terry MB, Thomassen M, Thompson J, Thull DL, Tischkowitz M, Tollenaar RAEM, Torres D, Troester MA, Truong T, Tung N, Untch M, Vachon CM, van Rensburg EJ, van Veen EM, Vega A, Viel A, Wappenschmidt B, Weitzel JN, Wendt C, Wieme G, Wolk A, Yang XR, Zheng W, Ziogas A, Zorn KK, Dunning AM, Lush M, Wang Q, McGuffog L, Parsons MT, Pharoah PDP, Fostira F, Toland AE, Andrulis IL, Ramus SJ, Swerdlow AJ, Greene MH, Chung WK, Milne RL, Chenevix-Trench G, Dörk T, Schmidt MK, Easton DF, Radice P, Hahnen E, Antoniou AC, Couch FJ, Nevanlinna H, Surrallés J, Peterlongo P.
    • NPJ Breast Cancer. 2019 Nov 1;5:38. doi: 10.1038/s41523-019-0127-5. eCollection 2019.
    • BRCA1 promoter methylation in peripheral blood is associated with the risk of triple-negative breast cancer.
    • Prajzendanc K, Domagała P, Hybiak J, Ryś J, Huzarski T, Szwiec M, Tomiczek-Szwiec J, Redelbach W, Sejda A, Gronwald J, Kluz T, Wiśniowski R, Cybulski C, Łukomska A, Białkowska K, Sukiennicki G, Kulczycka K, Narod SA, Wojdacz TK, Lubiński J, Jakubowska A.
    • Int J Cancer. 2019 Aug 30. doi: 10.1002/ijc.32655. [Epub ahead of print]
    • Risk factors for triple negative breast cancer among Latina women.
    • Rey-Vargas L, Sanabria Salas MC, Fejerman L, Serrano-Gómez SJ.
    • Cancer Epidemiol Biomarkers Prev. 2019 Aug 27. pii: cebp.0035.2019. doi: 10.1158/1055-9965.EPI-19-0035. [Epub ahead of print]
    • Influence of BRCA1 Germline Mutations in the Somatic Mutational Burden of Triple-Negative Breast Cancer.
    • Ferreira EN, Brianese RC, de Almeida RVB, Drummond RD, de Souza JE, da Silva IT, de Souza SJ, Carraro DM.
    • Transl Oncol. 2019 Aug 13;12(11):1453-1460. doi: 10.1016/j.tranon.2019.07.016. [Epub ahead of print]
    • Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy.
    • Shimomura A, Yonemori K, Yoshida M, Yoshida T, Yasojima H, Masuda N, Aogi K, Takahashi M, Naito Y, Shimizu S, Nakamura R, Hamada A, Michimae H, Hashimoto J, Yamamoto H, Kawachi A, Shimizu C, Fujiwara Y, Tamura K.
    • Transl Oncol. 2019 Aug 2;12(10):1386-1394. doi: 10.1016/j.tranon.2019.07.013. [Epub ahead of print]
    • Chromosomal radiosensitivity of triple negative breast cancer patients.
    • Francies FZ, Herd O, Cairns A, Nietz S, Murdoch M, Slabbert J, Claes KB, Vral A, Baeyens A.
    • Int J Radiat Biol. 2019 Jul 26:1-30. doi: 10.1080/09553002.2019.1649502. [Epub ahead of print]
    • Chromosome 12p amplification in triple-negative/BRCA1-mutated breast cancer associates with emergence of docetaxel resistance and carboplatin sensitivity.
    • Gómez-Miragaya J, Díaz-Navarro A, Tonda R, Beltran S, Palomero L, Palafox M, Dobrolecki LE, Huang C, Vasaikar S, Zhang B, Wulf GM, Collado-Solé A, Trinidad EM, Muñoz P, Paré L, Prat A, Bruna A, Caldas C, Arribas J, Soler-Monsó MT, Petit A, Balmaña J, Cruz C, Serra V, Pujana MA, Lewis MT, Puente XS, González-Suárez E.
    • Cancer Res. 2019 Jun 18. pii: canres.3835.2018. doi: 10.1158/0008-5472.CAN-18-3835. [Epub ahead of print]
    • Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.
    • Vinayak S, Tolaney SM, Schwartzberg L, Mita M, McCann G, Tan AR, Wahner-Hendrickson AE, Forero A, Anders C, Wulf GM, Dillon P, Lynce F, Zarwan C, Erban JK, Zhou Y, Buerstatte N, Graham JR, Arora S, Dezube BJ, Telli ML.
    • JAMA Oncol. 2019 Jun 13. doi: 10.1001/jamaoncol.2019.1029. [Epub ahead of print]

    Editorial:

    Immune Checkpoint and Poly(ADP–Ribose) Polymerase Inhibition for Recurrent Platinum-Resistant Ovarian and Metastatic Triple-Negative Breast Cancers.

    Press: Niraparib-Pembrolizumab Combo May Have Benefit in Ovarian, Breast Cancers. (Medscape)

    • Hereditary Susceptibility for Triple Negative Breast Cancer Associated With Western Sub-Saharan African Ancestry: Results From an International Surgical Breast Cancer Collaborative.
    • Newman LA, Jenkins B, Chen Y, Oppong JK, Adjei E, Jibril AS, Hoda S, Cheng E, Chitale D, Bensenhaver JM, Awuah B, Bekele M, Abebe E, Kyei I, Aitpillah F, Adinku M, Nathanson SD, Jackson L, Jiagge E, Merajver S, Petersen LF, Proctor E, Gyan KK, Martini R, Kittles R, Davis MB.
    • Ann Surg. 2019 Jul 6. doi: 10.1097/SLA.0000000000003459. [Epub ahead of print]
    • Homologous recombination deficiency in triple negative breast cancer.
    • Belli C, Duso BA, Ferraro E, Curigliano G.
    • Breast. 2019 Jun;45:15-21. doi: 10.1016/j.breast.2019.02.007. Epub 2019 Feb 20.
    • Review
    • Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) - Recommendations for Daily Routine Practice.
    • Schneeweiss A, Denkert C, Fasching PA, Fremd C, Gluz O, Kolberg-Liedtke C, Loibl S, Lück HJ.
    • Geburtshilfe Frauenheilkd. 2019 Jun;79(6):605-617. doi: 10.1055/a-0887-0285. Epub 2019 Jun 14.
    • BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer.
    • Solinas C, Marcoux D, Garaud S, Vitória JR, Van den Eynden G, de Wind A, De Silva P, Boisson A, Craciun L, Larsimont D, Piccart-Gebhart M, Detours V, t'Kint de Roodenbeke D, Willard-Gallo K.
    • Cancer Lett. 2019 May 28;450:88-97. doi: 10.1016/j.canlet.2019.02.027. Epub 2019 Feb 22.
    • Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy.
    • Al-Hilli Z, Choong G, Keeney MG, Visscher DW, Ingle JN, Goetz MP, Jakub JW.
    • Breast Cancer Res Treat. 2019 May 22. doi: 10.1007/s10549-019-05264-2. [Epub ahead of print]
    • Integrating poly(ADP-ribose) polymerase (PARP) inhibitors in the treatment of early breast cancer.
    • Garber HR, Litton JK.
    • Curr Opin Oncol. 2019 May;31(3):247-255. doi: 10.1097/CCO.0000000000000516.
    • Review
    • Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia.
    • Mahfoudh W, Bettaieb I, Ghedira R, Snoussi K, Bouzid N, Klayech Z, Gabbouj S, Remadi Y, Hassen E, Bouaouina N, Zakhama A.
    • J Transl Med. 2019 Apr 11;17(1):123. doi: 10.1186/s12967-019-1873-8.
    • Combined tumor sequencing and case/control analyses of RAD51C in breast cancer.
    • Li N, McInerny S, Zethoven M, Cheasley D, Lim BWX, Rowley SM, Devereux L, Grewal N, Ahmadloo S, Byrne D, Lee JEA, Li J, Fox SB, John T, Antill Y, Gorringe KL, James PA, Campbell IG.
    • J Natl Cancer Inst. 2019 Apr 5. pii: djz045. doi: 10.1093/jnci/djz045. [Epub ahead of print]
    • Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC.
    • Imanishi S, Naoi Y, Shimazu K, Shimoda M, Kagara N, Tanei T, Miyake T, Kim SJ, Noguchi S.
    • Breast Cancer Res Treat. 2019 Apr;174(3):627-637. doi: 10.1007/s10549-018-05120-9. Epub 2019 Jan 3.
    • The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis.
    • Caramelo O, Silva C, Caramelo F, Frutuoso C, Almeida-Santos T.
    • Hered Cancer Clin Pract. 2019 Mar 25;17:11. doi: 10.1186/s13053-019-0111-y. eCollection 2019.
    • Effect of AR antagonist combined with PARP1 inhibitor on sporadic triple-negative breast cancer bearing AR expression and methylation-mediated BRCA1 dysfunction.
    • Sang M, Meng L, Ma C, Liu S, Sang M, Chang S, Liu F, Lian Y, Geng C.
    • Biomed Pharmacother. 2019 Mar;111:169-177. doi: 10.1016/j.biopha.2018.11.136. Epub 2018 Dec 21.
    • Molecular mechanism of triple-negative breast cancer-associated BRCA1 and the identification of signaling pathways.
    • Qi F, Qin WX, Zang YS.
    • Oncol Lett. 2019 Mar;17(3):2905-2914. doi: 10.3892/ol.2019.9884. Epub 2019 Jan 3.
    • BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.
    • Mio C, Gerratana L, Bolis M, Caponnetto F, Zanello A, Barbina M, Di Loreto C, Garattini E, Damante G, Puglisi F.
    • Int J Cancer. 2019 Feb 15;144(4):755-766. doi: 10.1002/ijc.31898. Epub 2018 Dec 4.
    • Evaluation of the BRCAness phenotype and its correlations with clinicopathological features in triple-negative breast cancers.
    • Tian T, Shan L, Yang W, Zhou X, Shui R.
    • Hum Pathol. 2019 Feb;84:231-238. doi: 10.1016/j.humpath.2018.10.004. Epub 2018 Oct 16.
    • Triple-negative breast cancer: the reality in Chile and in Latin America.
    • Caglevic C, Anabalón J, Soza C, Milla E, Gaete F, Carrasco AM, Panay S, Gallardo C, Mahave M.
    • Ecancermedicalscience. 2019 Jan 22;13:893. doi: 10.3332/ecancer.2019.893. eCollection 2019.
    • Germline Mutations in BRCA1 and BRCA2 in Breast Cancer Patients with High Genetic Risk in Turkish Population.
    • Geredeli C, Yasar N, Sakin A.
    • Int J Breast Cancer. 2019 Jan 1;2019:9645147. doi: 10.1155/2019/9645147. eCollection 2019.
    • Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea.
    • Ryu JM, Choi HJ, Kim I, Nam SJ, Kim SW, Yu J, Lee SK, Choi DH, Park YH, Kim JW, Seo JS, Park JH, Lee JE, Kim SW; Korean Hereditary Breast Cancer Study Group.
    • Breast Cancer Res Treat. 2019 Jan;173(2):385-395. doi: 10.1007/s10549-018-5015-4. Epub 2018 Oct 22.
    • A Bayesian network meta-analysis of the efficacy of targeted therapies and chemotherapy for treatment of triple-negative breast cancer.
    • Chen H, Lu W, Zhang Y, Zhu X, Zhou J, Chen Y.
    • Cancer Med. 2019 Jan;8(1):383-399. doi: 10.1002/cam4.1892. Epub 2018 Dec 7.
    • Clinical and pathologic characteristics of breast cancer patients carrying the c.3481_3491del11 mutation.
    • El Tannouri R, Albuisson E, Jonveaux P, Luporsi E.
    • Fam Cancer. 2019 Jan;18(1):1-8. doi: 10.1007/s10689-018-0079-1.
    • Epidemiology of Breast Cancer in Women.
    • Coughlin SS.
    • Adv Exp Med Biol. 2019;1152:9-29. doi: 10.1007/978-3-030-20301-6_2.
    • Review
    • Treatment patterns, clinical outcomes, health resource utilization, and cost in patients with BRCA-mutated metastatic breast cancer treated in community oncology settings.
    • Houts AC, Olufade T, Shenolikar R, Walker MS, Schwartzberg LS.
    • Cancer Treat Res Commun. 2019;19:100121. doi: 10.1016/j.ctarc.2019.100121. Epub 2019 Feb 6.
    • BRCA1 Mutations Associated With Increased Risk of Brain Metastases in Breast Cancer: A 1: 2 Matched-pair Analysis.
    • Zavitsanos PJ, Wazer DE, Hepel JT, Wang Y, Singh K, Leonard KL.
    • Am J Clin Oncol. 2018 Dec;41(12):1252-1256. doi: 10.1097/COC.0000000000000466.
    • Menopausal Status and Outcomes of BRCA Mutation Carriers with Breast Cancer.
    • Carlson K, Chung A, Mirocha J, Donovan C, Estrada S, Siegel E, Giuliano A, Amersi F.
    • Am Surg. 2018 Oct 1;84(10):1584-1588.
    • Inherited Breast Cancer in Nigerian Women.
    • Zheng Y, Walsh T, Gulsuner S, Casadei S, Lee MK, Ogundiran TO, Ademola A, Falusi AG, Adebamowo CA, Oluwasola AO, Adeoye A, Odetunde A, Babalola CP, Ojengbede OA, Odedina S, Anetor I, Wang S, Huo D, Yoshimatsu TF, Zhang J, Felix GES, King MC, Olopade OI.
    • J Clin Oncol. 2018 Oct 1;36(28):2820-2825. doi: 10.1200/JCO.2018.78.3977. Epub 2018 Aug 21.

    Research News: Inherited breast cancer in Nigerian women. (FORCE XRAYS)

    • Genetic Markers in Triple-Negative Breast Cancer.
    • Sporikova Z, Koudelakova V, Trojanec R, Hajduch M.
    • Clin Breast Cancer. 2018 Oct;18(5):e841-e850. doi: 10.1016/j.clbc.2018.07.023. Epub 2018 Aug 4.
    • Impact of BRCA Mutation Status on Survival of Women With Triple-negative Breast Cancer.
    • Yadav S, Ladkany R, Yadav D, Alhalabi O, Khaddam S, Isaac D, Cardenas PY, Zakalik D.
    • Clin Breast Cancer. 2018 Oct;18(5):e1229-e1235. doi: 10.1016/j.clbc.2017.12.014. Epub 2017 Dec 30.
    • Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria.
    • Hoyer J, Vasileiou G, Uebe S, Wunderle M, Kraus C, Fasching PA, Thiel CT, Hartmann A, Beckmann MW, Lux MP, Reis A.
    • BMC Cancer. 2018 Sep 26;18(1):926. doi: 10.1186/s12885-018-4821-8.
    • Association Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis.
    • Chen H, Wu J, Zhang Z, Tang Y, Li X, Liu S, Cao S, Li X.
    • Front Pharmacol. 2018 Aug 21;9:909. doi: 10.3389/fphar.2018.00909. eCollection 2018.
    • Prevalence of BRCA1 and BRCA2 Mutations Among High-Risk Saudi Patients With Breast Cancer.
    • Abulkhair O, Al Balwi M, Makram O, Alsubaie L, Faris M, Shehata H, Hashim A, Arun B, Saadeddin A, Ibrahim E.
    • J Glob Oncol. 2018 Aug;(4):1-9. doi: 10.1200/JGO.18.00066.
    • Therapeutic landscape in mutational triple negative breast cancer.
    • Shi Y, Jin J, Ji W, Guan X.
    • Mol Cancer. 2018 Jul 14;17(1):99. doi: 10.1186/s12943-018-0850-9.
    • Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer.
    • Sztupinszki Z, Diossy M, Krzystanek M, Reiniger L, Csabai I, Favero F, Birkbak NJ, Eklund AC, Syed A, Szallasi Z.
    • NPJ Breast Cancer. 2018 Jul 2;4:16. doi: 10.1038/s41523-018-0066-6. eCollection 2018.
    • Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations.
    • Clifton K, Gutierrez-Barrera A, Ma J, Bassett R Jr., Litton J, Kuerer H, Moulder S, Albarracin C, Hortobagyi G, Arun B.
    • Breast Cancer Res Treat. 2018 Jul;170(1):101-109. doi: 10.1007/s10549-018-4727-9. Epub 2018 Feb 22.
    • Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer.
    • Afghahi A, Purington N, Han SS, Desai M, Pierson E, Mathur MB, Seto T, Thompson CA, Rigdon J, Telli ML, Badve SS, Curtis CN, West RB, Horst K, Gomez SL, Ford JM, Sledge GW, Kurian AW.
    • Clin Cancer Res. 2018 Jun 15;24(12):2851-2858. doi: 10.1158/1078-0432.CCR-17-1323. Epub 2018 Mar 26.
    • Reproductive history, breast-feeding and risk of triple negative breast cancer: The Breast Cancer Etiology in Minorities (BEM) study.
    • John EM, Hines LM, Phipps AI, Koo J, Longacre TA, Ingles SA, Baumgartner KB, Slattery ML, Wu AH.
    • Int J Cancer. 2018 Jun 1;142(11):2273-2285. doi: 10.1002/ijc.31258. Epub 2018 Jan 30.
    • Reported Biologic Differences in Breast Cancer by Race Due to Disparities in Screening.
    • Denu RA.
    • JAMA Oncol. 2018 Jun 1;4(6):883. doi: 10.1001/jamaoncol.2017.5906.

    Original Research:

    Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas.

    Letter, Reply:

    Reported Biologic Differences in Breast Cancer by Race Due to Disparities in Screening-Reply.

    • Risks and protective factors for triple negative breast cancer with a focus on micronutrients and infections.
    • Horakova D, Bouchalova K, Cwiertka K, Stepanek L, Vlckova J, Kollarova H.
    • Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018 Jun;162(2):83-89. doi: 10.5507/bp.2018.014. Epub 2018 May 15.
    • The PDGF pathway in breast cancer is linked to tumour aggressiveness, triple-negative subtype and early recurrence.
    • Jansson S, Aaltonen K, Bendahl PO, Falck AK, Karlsson M, Pietras K, Rydén L.
    • Breast Cancer Res Treat. 2018 Jun;169(2):231-241. doi: 10.1007/s10549-018-4664-7. Epub 2018 Jan 29.
    • Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy.
    • Al-Subhi N, Ali R, Abdel-Fatah T, Moseley PM, Chan SYT, Green AR, Ellis IO, Rakha EA, Madhusudan S.
    • Breast Cancer Res Treat. 2018 Jun;169(2):277-286. doi: 10.1007/s10549-018-4683-4. Epub 2018 Feb 2.
    • First international TNBC conference meeting report.
    • Rida P, Ogden A, Ellis IO, Varga Z, Wolff AC, Traina TA, Hatzis C, Palmer JR, Ambrosone CB, Lehmann BD, Nanda R, Montgomery Rice V, Brawley OW, Torres MA, Rakha E, Aneja R.
    • Breast Cancer Res Treat. 2018 Jun;169(3):407-412. doi: 10.1007/s10549-018-4692-3. Epub 2018 Feb 8.
    • Review, Conference report
    • Alarming Burden of Triple-negative Breast Cancer in India.
    • Thakur KK, Bordoloi D, Kunnumakkara AB.
    • Clin Breast Cancer. 2018 Jun;18(3):e393-e399. doi: 10.1016/j.clbc.2017.07.013. Epub 2017 Jul 20.
    • Review
    • Glucocorticoid receptor overexpression slightly shifts microRNA expression patterns in triple-negative breast cancer.
    • Buschmann D, González R, Kirchner B, Mazzone C, Pfaffl MW, Schelling G, Steinlein O, Reithmair M.
    • Int J Oncol. 2018 Jun;52(6):1765-1776. doi: 10.3892/ijo.2018.4336. Epub 2018 Mar 27.
    • Comparison of BRCA1 Expression between Triple-Negative and Luminal Breast Tumors.
    • Darbeheshti F, Izadi P, Emami Razavi AN, Yekaninejad M, Tavakkoly Bazzaz J.
    • Iran Biomed J. 2018 May 1;22(3):210-4. Epub 2017 Jun 25.
    • Triple negative breast cancer: new therapeutic approaches and BRCA status.
    • Guney Eskiler G, Cecener G, Egeli U, Tunca B.
    • APMIS. 2018 May;126(5):371-379. doi: 10.1111/apm.12836.
    • Review
    • Patterns of care and outcomes among triple-negative early breast cancer patients in South Western Sydney.
    • Naher S, Tognela A, Moylan E, Adams DH, Kiely BE.
    • Intern Med J. 2018 May;48(5):567-572. doi: 10.1111/imj.13628.
    • Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.
    • Bareche Y, Venet D, Ignatiadis M, Aftimos P, Piccart M, Rothe F, Sotiriou C.
    • Ann Oncol. 2018 Apr 1;29(4):895-902. doi: 10.1093/annonc/mdy024.
    • Genetic alterations in sporadic triple negative breast cancer.
    • Pop LA, Cojocneanu-Petric RM, Pileczki V, Morar-Bolba G, Irimie A, Lazar V, Lombardo C, Paradiso A, Berindan-Neagoe I.
    • Breast. 2018 Apr;38:30-38. doi: 10.1016/j.breast.2017.11.006. Epub 2017 Dec 5.
    • Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
    • Telli ML, Hellyer J, Audeh W, Jensen KC, Bose S, Timms KM, Gutin A, Abkevich V, Peterson RN, Neff C, Hughes E, Sangale Z, Jones J, Hartman AR, Chang PJ, Vinayak S, Wenstrup R, Ford JM.
    • Breast Cancer Res Treat. 2018 Apr;168(3):625-630. doi: 10.1007/s10549-017-4624-7. Epub 2017 Dec 23.
    • Clinicopathological and Molecular Study of Triple-Negative Breast Cancer in Algerian Patients.
    • Gaceb H, Cherbal F, Bakour R, Ould-Rouis A, Mahfouf H.
    • Pathol Oncol Res. 2018 Apr;24(2):297-308. doi: 10.1007/s12253-017-0242-2. Epub 2017 May 6.
    • Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
    • Engel C, Rhiem K, Hahnen E, Loibl S, Weber KE, Seiler S, Zachariae S, Hauke J, Wappenschmidt B, Waha A, Blümcke B, Kiechle M, Meindl A, Niederacher D, Bartram CR, Speiser D, Schlegelberger B, Arnold N, Wieacker P, Leinert E, Gehrig A, Briest S, Kast K, Riess O, Emons G, Weber BHF, Engel J, Schmutzler RK; German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC).
    • BMC Cancer. 2018 Mar 7;18(1):265. doi: 10.1186/s12885-018-4029-y.
    • Race Disparities in the Contribution of miRNA Isoforms and tRNA-Derived Fragments to Triple-Negative Breast Cancer.
    • Telonis AG, Rigoutsos I.
    • Cancer Res. 2018 Mar 1;78(5):1140-1154. doi: 10.1158/0008-5472.CAN-17-1947. Epub 2017 Dec 11.
    • Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple Negative Breast Cancer.
    • Liu H, Murphy CJ, Karreth FA, Emdal KB, White FM, Elemento O, Toker A, Wulf GM, Cantley LC.
    • Cancer Discov. 2018 Mar;8(3):354-369. doi: 10.1158/2159-8290.CD-17-0679. Epub 2017 Dec 4.
    • p63 isoforms in triple-negative breast cancer: ΔNp63 associates with the basal phenotype whereas TAp63 associates with androgen receptor, lack of BRCA mutation, PTEN and improved survival.
    • Coates PJ, Nenutil R, Holcakova J, Nekulova M, Podhorec J, Svoboda M, Vojtesek B.
    • Virchows Arch. 2018 Mar;472(3):351-359. doi: 10.1007/s00428-018-2324-2. Epub 2018 Feb 27.
    • A20 Constitutional methylation of BRCA1 gene in breast cancer.
    • Prajzendanc K, Kaczmarek K, Łukomska A, Sukiennicki G, Szwiec M, Huzarski T, Wojdacz TK, Lubiński J, Jakubowska A.
    • Hered Cancer Clin Pract. 2018 Feb 28;16(Suppl 1):A20. Meeting abstracts from Clinical Genetics of Cancer 2017; Szczecin, Poland. 21-22 September 2017. doi: 10.1186/s13053-018-0087-z.
    • Conference abstract
    • Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer.
    • Stover DG, Parsons HA, Ha G, Freeman SS, Barry WT, Guo H, Choudhury AD, Gydush G, Reed SC, Rhoades J, Rotem D, Hughes ME, Dillon DA, Partridge AH, Wagle N, Krop IE, Getz G, Golub TR, Love JC, Winer EP, Tolaney SM, Lin NU, Adalsteinsson VA.
    • J Clin Oncol. 2018 Feb 20;36(6):543-553. doi: 10.1200/JCO.2017.76.0033. Epub 2018 Jan 3.

    Editorial:

    Circulating Tumor DNA Guides Prognosis in Metastatic Triple-Negative Breast Cancer.

    • Metabolic profiles of triple-negative and luminal A breast cancer subtypes in African-American identify key metabolic differences.
    • Tayyari F, Gowda GAN, Olopade OF, Berg R, Yang HH, Lee MP, Ngwa WF, Mittal SK, Raftery D, Mohammed SI.
    • Oncotarget. 2018 Feb 7;9(14):11677-11690. doi: 10.18632/oncotarget.24433. eCollection 2018 Feb 20.
    • Survival and mutation status in breast cancer patients under age 40.
    • [No author given]
    • FORCE. XRAYS. 2018 Feb 15.

    Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.

    Commentary:

    Breast cancer in young women: do BRCA1 or BRCA2 mutations matter?

    • Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy.
    • Al-Subhi N, Ali R, Abdel-Fatah T, Moseley RM, Chan SYT, Green AR, Ellis IO, Rakha EA.
    • Breast Cancer Res Treat. 2018 Feb 2. doi: 10.1007/s10549-018-4683-4. [Epub ahead of print]
    • Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.
    • Copson ER, Maishman TC, Tapper WJ, Cutress RI, Greville-Heygate S, Altman DG, Eccles B, Gerty S, Durcan LT, Jones L, Evans DG, Thompson AM, Pharoah P, Easton DF, Dunning AM, Hanby A, Lakhani S, Eeles R, Gilbert FJ, Hamed H, Hodgson S, Simmonds P, Stanton L, Eccles DM.
    • Lancet Oncol. 2018 Feb;19(2):169-180. doi: 10.1016/S1470-2045(17)30891-4. Epub 2018 Jan 11.

    Commentary:

    Breast cancer in young women: do BRCA1 or BRCA2 mutations matter?

    Research news:

    Young women with BRCA mutation can safely postpone radical surgery.

    Press: Survival After Breast Cancer 'Unaffected by BRCA Status' (Medscape)

    Research news: Survival and mutation status in breast cancer patients under age 40. (FORCE: XRAYS)

    • Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going.
    • Omarini C, Guaitoli G, Pipitone S, Moscetti L, Cortesi L, Cascinu S, Piacentini F.
    • Cancer Manag Res. 2018 Jan 15;10:91-103. doi: 10.2147/CMAR.S146658. eCollection 2018.
    • Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer.
    • Stover DG, Parsons HA, Ha G, Freeman SS, Barry WT, Guo H, Choudhury AD, Gydush G, Reed SC, Rhoades J, Rotem D, Hughes ME, Dillon DA, Partridge AH, Wagle N, Krop IE, Getz G, Golub TR, Love JC, Winer EP, Tolaney SM, Lin NU, Adalsteinsson VA.
    • J Clin Oncol. 2018 Jan 3:JCO2017760033. doi: 10.1200/JCO.2017.76.0033. [Epub ahead of print]

    Editorial:

    Circulating Tumor DNA Guides Prognosis in Metastatic Triple-Negative Breast Cancer.

    • Expression of breast cancer type 1 and its relation with expression of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2/neu in breast carcinoma on trucut biopsy specimens.
    • Verma D, Agarwal K, Tudu SK.
    • Indian J Pathol Microbiol. 2018 Jan-Mar;61(1):31-38. doi: 10.4103/IJPM.IJPM_393_16.
    • Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.
    • Leon-Ferre RA, Polley MY, Liu H, Gilbert JA, Cafourek V, Hillman DW, Elkhanany A, Akinhanmi M, Lilyquist J, Thomas A, Negron V, Boughey JC, Liu MC, Ingle JN, Kalari KR, Couch FJ, Visscher DW, Goetz MP.
    • Breast Cancer Res Treat. 2018 Jan;167(1):89-99. doi: 10.1007/s10549-017-4499-7. Epub 2017 Sep 14.
    • Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity.
    • Reddy SM, Barcenas CH, Sinha AK, Hsu , Moulder , Tripathy D, Hortobagyi GN, Valero V.
    • Br J Cancer. 2018 Jan;118(1):17-23. doi: 10.1038/bjc.2017.379. Epub 2017 Dec 12.
    • Apoptosis regulator Bcl-2 is an independent prognostic marker for worse overall survival in triple-negative breast cancer patients.
    • Ozretic P, Alvir I, Sarcevic B, Vujaskovic Z, Rendic-Miocevic Z, Roguljic A, Beketic-Oreskovic L.
    • Int J Biol Markers. 2018 Jan;33(1):109-115. doi: 10.5301/ijbm.5000291.
    • Breast Cancer Disparities: How Can We Leverage Genomics to Improve Outcomes?
    • Davis MB, Newman LA.
    • Surg Oncol Clin N Am. 2018 Jan;27(1):217-234. doi: 10.1016/j.soc.2017.07.009.
    • Review
    • Differential Claudin 3 and EGFR Expression Predicts BRCA1 Mutation in Triple-Negative Breast Cancer.
    • Danzinger S, Tan YY, Rudas M, Kastner MT, Weingartshofer S, Muhr D, Singer CF; kConFab Investigators.
    • Cancer Invest. 2018;36(7):378-388. doi: 10.1080/07357907.2018.1499934. Epub 2018 Aug 24.
    • miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
    • Li HY, Liang JL, Kuo YL, Lee HH, Calkins MJ, Chang HT, Lin FC, Chen YC, Hsu TI, Hsiao M, Ger LP, Lu PJ.
    • Breast Cancer Res. 2017 Dec 19;19(1):133. doi: 10.1186/s13058-017-0918-2.
    • Metabolomics reveals novel blood plasma biomarkers associated to the BRCA1-mutated phenotype of human breast cancer.
    • Roig B, Rodríguez-Balada M, Samino S, Lam EW, Guaita-Esteruelas S, Gomes AR, Correig X, Borràs J, Yanes O, Gumà J.
    • Sci Rep. 2017 Dec 19;7(1):17831. doi: 10.1038/s41598-017-17897-8.
    • Secretory leukocyte protease inhibitor (SLPI) as a potential target for inhibiting metastasis of triple-negative breast cancers.
    • Kozin SV, Maimon N, Wang R, Gupta N, Munn L, Jain RK, Garkavtsev I.
    • Oncotarget. 2017 Nov 26;8(65):108292-108302. doi: 10.18632/oncotarget.22660. eCollection 2017 Dec 12.
    • Downregulation of miR-221-3p and upregulation of its target gene PARP1 are prognostic biomarkers for triple negative breast cancer patients and associated with poor prognosis.
    • Deng L, Lei Q, Wang Y, Wang Z, Xie G, Zhong X, Wang Y, Chen N, Qiu Y, Pu T, Bu H, Zheng H.
    • Oncotarget. 2017 Oct 6;8(65):108712-108725. doi: 10.18632/oncotarget.21561. eCollection 2017 Dec 12.
    • Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer.
    • Karn T, Jiang T, Hatzis C, Sänger N, El-Balat A, Rody A, Holtrich U, Becker S, Bianchini G, Pusztai L.
    • JAMA Oncol. 2017 Dec 1;3(12):1707-1711. doi: 10.1001/jamaoncol.2017.2140.
    • Biology and Etiology of Young-Onset Breast Cancers among Premenopausal African American Women: Results from the AMBER Consortium.
    • Chollet-Hinton L, Olshan AF, Nichols HB, Anders CK, Lund JL, Allott EH, Bethea TN, Hong CC, Cohen SM, Khoury T, Zirpoli GR, Borges VF, Rosenberg LA, Bandera EV, Ambrosone CB, Palmer JR, Troester MA.
    • Cancer Epidemiol Biomarkers Prev. 2017 Dec;26(12):1722-1729. doi: 10.1158/1055-9965.EPI-17-0450. Epub 2017 Sep 13.
    • A niche that triggers aggressiveness within BRCA1-IRIS overexpressing triple negative tumors is supported by reciprocal interactions with the microenvironment.
    • Ryan D, Bogan D, Davies J, Koziol J, ElShamy WM.
    • Oncotarget. 2017 Sep 14;8(61):103182-103206. doi: 10.18632/oncotarget.20892. eCollection 2017 Nov 28.
    • Tumor Infiltrating Lymphocytes May be Predictive in African-American Women with Triple-Negative Breast Cancer.
    • Schieszer J.
    • OncoTherapy Network. 2017 Nov 2.
    • Breast cancer in Africa: prevalence, treatment options, herbal medicines, and socioeconomic determinants.
    • Lukong KE, Ogunbolude Y, Kamdem JP.
    • Breast Cancer Res Treat. 2017 Nov;166(2):351-365. doi: 10.1007/s10549-017-4408-0. Epub 2017 Aug 4.
    • Review
    • A functional BRCA1 coding sequence genetic variant contributes to prognosis of triple-negative breast cancer, especially after radiotherapy.
    • Shi M, Ma F, Liu J, Xing H, Zhu H, Yu J, Yang M.
    • Breast Cancer Res Treat. 2017 Nov;166(1):109-116. doi: 10.1007/s10549-017-4395-1. Epub 2017 Jul 25.
    • Roles of BCCIP deficiency in mammary tumorigenesis.
    • Droz-Rosario R, Lu H, Liu J, Liu NA, Ganesan S, Xia B, Haffty BG, Shen Z.
    • Breast Cancer Res. 2017 Oct 18;19(1):115. doi: 10.1186/s13058-017-0907-5.
    • Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
    • Gabaldó Barrios X, Sarabia Meseguer MD, Marín Vera M, Sánchez Bermúdez AI, Macías Cerrolaza JA, Sánchez Henarejos P, Zafra Poves M, García Hernández MR, Cuevas Tortosa E, Aliaga Baño Á, Castillo Guardiola V, Martínez Hernández P, Tovar Zapata I, Martínez Barba E, Ayala de la Peña F, Alonso Romero JL, Noguera Velasco JA, Ruiz Espejo F.
    • Fam Cancer. 2017 Oct;16(4):477-489. doi: 10.1007/s10689-017-9985-x.
    • P53 alteration in morphologically normal/benign breast luminal cells in BRCA carriers with or without history of breast cancer.
    • Wang X, El-Halaby AA, Zhang H, Yang Q, Laughlin TS, Rothberg PG, Skinner K, Hicks DG.
    • Hum Pathol. 2017 Oct;68:22-25. doi: 10.1016/j.humpath.2017.04.007. Epub 2017 Apr 21.
    • miR-10b, miR-26a, miR-146a And miR-153 Expression in Triple Negative Vs Non Triple Negative Breast Cancer: Potential Biomarkers.
    • Fkih M'hamed I, Privat M, Trimeche M, Penault-Llorca F, Bignon YJ, Kenani A.
    • Pathol Oncol Res. 2017 Oct;23(4):815-827. doi: 10.1007/s12253-017-0188-4. Epub 2017 Jan 18.
    • Identification of Interacting Stromal Axes in Triple-Negative Breast Cancer.
    • Saleh SMI, Bertos N, Gruosso T, Gigoux M, Souleimanova M, Zhao H, Omeroglu A, Hallett MT, Park M.
    • Cancer Res. 2017 Sep 1;77(17):4673-4683. doi: 10.1158/0008-5472.CAN-16-3427. Epub 2017 Jun 26.
    • The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.
    • Severson TM, Wolf DM, Yau C, Peeters J, Wehkam D, Schouten PC, Chin SF, Majewski IJ, Michaut M, Bosma A, Pereira B, Bismeijer T, Wessels L, Caldas C, Bernards R, Simon IM, Glas AM, Linn S, van 't Veer L.
    • Breast Cancer Res. 2017 Aug 25;19(1):99. doi: 10.1186/s13058-017-0861-2.
    • DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.
    • Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, Olopade O, van 't Veer L.
    • NPJ Breast Cancer. 2017 Aug 25;3:31. doi: 10.1038/s41523-017-0025-7. eCollection 2017.
    • Whole-Exome Sequencing of Metaplastic Breast Carcinoma Indicates Monoclonality with Associated Ductal Carcinoma Component.
    • Avigdor BE, Beierl K, Gocke CD, Zabransky DJ, Cravero K, Kyker-Snowman K, Button B, Chu D, Croessmann S, Cochran RL, Connolly RM, Park BH, Wheelan SJ, Cimino-Mathews A.
    • Clin Cancer Res. 2017 Aug 15;23(16):4875-4884. doi: 10.1158/1078-0432.CCR-17-0108. Epub 2017 Apr 19.
    • Genomic analysis of inherited breast cancer among Palestinian women: Genetic heterogeneity and a founder mutation in TP53.
    • Lolas Hamameh S, Renbaum P, Kamal L, Dweik D, Salahat M, Jaraysa T, Abu Rayyan A, Casadei S, Mandell JB, Gulsuner S, Lee MK, Walsh T, King MC, Levy-Lahad E, Kanaan M.
    • Int J Cancer. 2017 Aug 15;141(4):750-756. doi: 10.1002/ijc.30771. Epub 2017 May 19.
    • Clinical Activity of Pembrolizumab in a Patient With Metastatic Triple-Negative Breast Cancer Without Tumor Programmed Death-Ligand 1 Expression: A Case Report and Correlative Biomarker Analysis.
    • Bhatti S, Heldstab J, Lehn C, Tawfik O, Ash RM, Hout DR, Seitz RS, Bailey DB, O’Dea AP, Jensen RA, Fan F, Khan QJ, Godwin AK, Sharma P.
    • JCO Precis Oncol. doi: 10.1200/PO.17.00032. Epub 2017 Aug 7.
    • The role of BRCA status on prognosis in patients with triple-negative breast cancer.
    • Xie Y, Gou Q, Wang Q, Zhong X, Zheng H.
    • Oncotarget. 2017 Aug 3;8(50):87151-87162. doi: 10.18632/oncotarget.19895. eCollection 2017 Oct 20.
    • Identification of new tumor suppressor genes in triple-negative breast cancer.
    • Rangel R, Guzman-Rojas L, Kodama T, Kodama M, Newberg JY, Copeland NG, Jenkins NA.
    • Cancer Res. 2017 Aug 1;77(15):4089-4101. doi: 10.1158/0008-5472.CAN-17-0785. Epub 2017 Jul 19.
    • Comprehensive Analysis of the Unfolded Protein Response in Breast Cancer Subtypes.
    • Jiang D, Turner B, Song J, Li R, Diehn M, Le QT, Khatri P, Koong AC.
    • JCO Precis Oncol. doi: 10.1200/PO.16.00073. Epub 2017 Jul 26.
    • NHERF1 together with PARP1 and BRCA1 expression as a new potential biomarker to stratify breast cancer patients.
    • Mangia A, Scarpi E, Partipilo G, Schirosi L, Opinto G, Giotta F, Simone G.
    • Oncotarget. 2017 Jul 22;8(39):65730-65742. doi: 10.18632/oncotarget.19444. eCollection 2017 Sep 12.
    • Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events.
    • Meißner T, Mark A, Williams C, Berdel WE, Wiebe S, Kerkhoff A, Wardelmann E, Gaiser T, Müller-Tidow C, Rosenstiel P, Arnold N, Leyland-Jones B, Franke A, Stanulla M, Forster M.
    • Cold Spring Harb Mol Case Stud. 2017 Jul 5;3(4). pii: a001677. doi: 10.1101/mcs.a001677. Print 2017 Jul.
    • Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression.
    • Reyes ME, Fujii T, Branstetter D, Krishnamurthy S, Masuda H, Wang X, Reuben JM, Woodward WA, Edwards BJ, Hortobagyi GN, Tripathy D, Dougall WC, Eckhardt BL, Ueno NT.
    • Breast Cancer Res Treat. 2017 Jul;164(1):57-67. doi: 10.1007/s10549-017-4233-5. Epub 2017 Apr 17.
    • Integrative analysis of genomic alterations in triple-negative breast cancer in association with homologous recombination deficiency.
    • Kawazu M, Kojima S, Ueno T, Totoki Y, Nakamura H, Kunita A, Qu W, Yoshimura J, Soda M, Yasuda T, Hama N, Saito-Adachi M, Sato K, Kohsaka S, Sai E, Ikemura M, Yamamoto S, Ogawa T, Fukayama M, Tada K, Seto Y, Morishita S, Hazama S, Shibata T, Yamashita Y, Mano H.
    • PLoS Genet. 2017 Jun 21;13(6):e1006853. doi: 10.1371/journal.pgen.1006853. eCollection 2017 Jun.
    • Clinical value of R-spondins in triple-negative and metaplastic breast cancers.
    • Coussy F, Lallemand F, Vacher S, Schnitzler A, Chemlali W, Caly M, Nicolas A, Richon S, Meseure D, El Botty R, De-Plater L, Fuhrmann L, Dubois T, Roman-Roman S, Dangles-Marie V, Marangoni E, Bièche I.
    • Br J Cancer. 2017 Jun 6;116(12):1595-1603. doi: 10.1038/bjc.2017.131. Epub 2017 May 4.
    • Health-related quality of life in Black breast cancer survivors with and without triple-negative breast cancer (TNBC).
    • Vadaparampil ST, Christie J, Donovan KA, Kim J, Augusto B, Kasting ML, Holt CL, Ashing K, Halbert CH, Pal T.
    • Breast Cancer Res Treat. 2017 Jun;163(2):331-342. doi: 10.1007/s10549-017-4173-0. Epub 2017 Mar 3.
    • A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
    • Buys SS, Sandbach JF, Gammon A, Patel G, Kidd J, Brown KL, Sharma L, Saam J, Lancaster J, Daly MB.
    • Cancer. 2017 May 15;123(10):1721-1730. doi: 10.1002/cncr.30498. Epub 2017 Jan 13.
    • The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
    • Bogan D, Meile L, El Bastawisy A, Yousef HF, Zekri AN, Bahnassy AA, ElShamy WM.
    • BMC Cancer. 2017 May 12;17(1):329. doi: 10.1186/s12885-017-3283-8.
    • Health Disparities and Triple-Negative Breast Cancer in African American Women: A Review.
    • Newman LA, Kaljee LM.
    • JAMA Surg. 2017 May 1;152(5):485-493. doi: 10.1001/jamasurg.2017.0005.
    • Review
    • Risk factors associated with the triple-negative breast cancer subtype within four race/ethnicities.
    • Parise CA, Caggiano V.
    • Breast Cancer Res Treat. 2017 May;163(1):151-158. doi: 10.1007/s10549-017-4159-y. Epub 2017 Feb 17.
    • Alcohol Intake and Breast Cancer Risk in African American Women from the AMBER Consortium.
    • Williams LA, Olshan AF, Hong CC, Bandera EV, Rosenberg L, Cheng TD, Lunetta KL, McCann SE, Poole C, Kolonel LN, Palmer JR, Ambrosone CB, Troester MA.
    • Cancer Epidemiol Biomarkers Prev. 2017 May;26(5):787-794. doi: 10.1158/1055-9965.EPI-16-0792. Epub 2017 Apr 18.
    • Practical Approach to Triple-Negative Breast Cancer.
    • Gadi VK, Davidson NE.
    • J Oncol Pract. 2017 May;13(5):293-300. doi: 10.1200/JOP.2017.022632.

    Commentary, Review:

    Outstanding Questions in the Clinical Management of Triple-Negative Breast Cancer

    Free Medscape version: Practical Approach to Triple-Negative Breast Cancer. Medscape

    • Triple-Negative Breast Cancer: Current Practice and Future Directions.
    • Costa RLB, Gradishar WJ.
    • J Oncol Pract. 2017 May;13(5):301-303. doi: 10.1200/JOP.2017.023333.
    • Outstanding Questions in the Clinical Management of Triple-Negative Breast Cancer.
    • Gruber JJ, Telli ML.
    • J Oncol Pract. 2017 May;13(5):305-307. doi: 10.1200/JOP.2017.023341.

    Review:

    Practical Approach to Triple-Negative Breast Cancer.

    • E3 Ubiquitin Ligase UBR5 Drives the Growth and Metastasis of Triple-Negative Breast Cancer.
    • Liao L, Song M, Li X, Tang L, Zhang T, Zhang L, Pan Y, Chouchane L, Ma X.
    • Cancer Res. 2017 Apr 15;77(8):2090-2101. doi: 10.1158/0008-5472.CAN-16-2409. Epub 2017 Mar 22.
    • Examining the common aetiology of serous ovarian cancers and basal-like breast cancers using double primaries.
    • Begg CB, Rice MS, Zabor EC, Tworoger SS.
    • Br J Cancer. 2017 Apr 11;116(8):1088-1091. doi: 10.1038/bjc.2017.73. Epub 2017 Mar 23.
    • Therapeutic Strategies in Triple-Negative Breast Cancer.
    • Paradiso A, Singer CF.
    • Breast Care (Basel). 2017 Mar;12(1):6-7. doi: 10.1159/000460238. Epub 2017 Feb 28.

    Review:

    Biological Subtypes of Triple-Negative Breast Cancer.

    Review:

    Germline Mutations in Triple-Negative Breast Cancer.

    Review:

    Therapeutic Advances and New Directions for Triple-Negative Breast Cancer.

    • Biological Subtypes of Triple-Negative Breast Cancer.
    • Hubalek M, Czech T, Müller H.
    • Breast Care (Basel). 2017 Mar;12(1):8-14. doi: 10.1159/000455820. Epub 2017 Feb 20.

    Editorial:

    Therapeutic Strategies in Triple-Negative Breast Cancer.

    • Germline Mutations in Triple-Negative Breast Cancer.
    • Hahnen E, Hauke J, Engel C, Neidhardt G, Rhiem K, Schmutzler RK.
    • Breast Care (Basel). 2017 Mar;12(1):15-19. doi: 10.1159/000455999. Epub 2017 Feb 24.

    Editorial:

    Therapeutic Strategies in Triple-Negative Breast Cancer.

    • Therapeutic Advances and New Directions for Triple-Negative Breast Cancer.
    • Andreopoulou E, Kelly CM, McDaid HM.
    • Breast Care (Basel). 2017 Mar;12(1):21-28. doi: 10.1159/000455821. Epub 2017 Feb 7.

    Editorial:

    Therapeutic Strategies in Triple-Negative Breast Cancer.

    • MiR-16: A novel hereditary marker in breast cancer and their offspring.
    • Usmani A, Shoro AA, Shirazi B, Memon Z, Hussain M.
    • J Pak Med Assoc. 2017 Mar;67(3):446-450.
    • Differences in the mutational landscape of triple-negative breast cancer in African Americans and Caucasians.
    • Ademuyiwa FO, Tao Y, Luo J, Weilbaecher K, Ma CX.
    • Breast Cancer Res Treat. 2017 Feb;161(3):491-499. doi: 10.1007/s10549-016-4062-y. Epub 2016 Dec 3.
    • Reproductive factors and the risk of triple-negative breast cancer in white women and African-American women: a pooled analysis.
    • Ma H, Ursin G, Xu X, Lee E, Togawa K, Duan L, Lu Y, Malone KE, Marchbanks PA, McDonald JA, Simon MS, Folger SG, Sullivan-Halley J, Deapen DM, Press MF, Bernstein L.
    • Breast Cancer Res. 2017 Jan 13;19(1):6. doi: 10.1186/s13058-016-0799-9.
    • Triple Negative Breast Cancer at the University Hospital Mohammed VI – Oujda.
    • Al jarroudi O, Abda N, Brahmi S, Afqir S.
    • Asian Pac J Cancer Prev. 2017 Jan 1;18(1):195-200.
    • Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family.
    • Geyer FC, Berman SH, Marchiò C, Burke KA, Guerini-Rocco E, Piscuoglio S, Ng CK, Pareja F, Wen HY, Hodi Z, Schnitt SJ, Rakha EA, Ellis IO, Norton L, Weigelt B, Reis-Filho JS.
    • Mod Pathol. 2017 Jan;30(1):69-84. doi: 10.1038/modpathol.2016.161. Epub 2016 Oct 7.
    • Clinical Characteristics in Patients with Triple Negative Breast Cancer.
    • Yeh J, Chun J, Schwartz S, Wang A, Kern E, Guth AA, Axelrod D, Shapiro R, Schnabel F.
    • Int J Breast Cancer. 2017;2017:1796145. doi: 10.1155/2017/1796145. Epub 2017 Aug 17.
    • An ovarian mass after breast cancer: Metachronous carcinoma or metastasis? A case report.
    • Makris GM, Marinelis A, Battista MJ, Chrelias C, Papantoniou N.
    • Int J Surg Case Rep. 2017;31:106-108. doi: 10.1016/j.ijscr.2016.12.022. Epub 2016 Dec 30.
    • BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer.
    • Mori H, Kubo M, Nishimura R, Osako T, Arima N, Okumura Y, Okido M, Yamada M, Kai M, Kishimoto J, Miyazaki T, Oda Y, Otsuka T, Nakamura M.
    • PLoS One. 2016 Dec 15;11(12):e0167016. doi: 10.1371/journal.pone.0167016. eCollection 2016.
    • Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants.
    • Pareja F, Geyer FC, Marchiò C, Burke KA, Weigelt B, Reis-Filho JS.
    • NPJ Breast Cancer. 2016 Nov 16;2:16036. doi: 10.1038/npjbcancer.2016.36. eCollection 2016.
    • Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.
    • Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L.
    • Nat Rev Clin Oncol. 2016 Nov;13(11):674-690. doi: 10.1038/nrclinonc.2016.66. Epub 2016 May 17.
    • Review
    • Triple negative breast cancer in North of Morocco: clinicopathologic and prognostic features.
    • Derkaoui T, Bakkach J, Mansouri M, Loudiyi A, Fihri M, Alaoui FZ, Barakat A, El Yemlahi B, Bihri H, Nourouti NG, Mechita MB.
    • BMC Womens Health. 2016 Oct 22;16(1):68.
    • Mechanism of serum miR-21 in the pathogenesis of familial and triple negative breast cancer.
    • Yang L, Feng Y, Qi P, Xu S, Zhou Y.
    • J Biol Regul Homeost Agents. 2016 Oct-Dec;30(4):1041-1045.
    • Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis.
    • Baretta Z, Mocellin S, Goldin E, Olopade OI, Huo D.
    • Medicine (Baltimore). 2016 Oct;95(40):e4975.
    • Biology and Management of Patients With Triple-Negative Breast Cancer.
    • Sharma P.
    • Oncologist. 2016 Sep;21(9):1050-62. doi: 10.1634/theoncologist.2016-0067. Epub 2016 Jul 11.
    • "An addendum to breast cancer": the triple negative experience.
    • Turkman YE, Kennedy HP, Harris LN, Knobf MT.
    • Support Care Cancer. 2016 Sep;24(9):3715-21. doi: 10.1007/s00520-016-3184-4. Epub 2016 Apr 1.
    • Prevalence of Triple-Negative Breast Cancer in India: Systematic Review and Meta-Analysis.
    • Sandhu GS, Erqou S, Patterson H, Mathew A.
    • J Glob Oncol. 2016 Jun 29. doi: 10.1200/JGO.2016.005397. [Epub ahead of print]
    • Recreational physical activity and risk of triple negative breast cancer in the California Teachers Study.
    • Ma H, Xu X, Clague J, Lu Y, Togawa K, Wang SS, Clarke CA, Lee E, Park HL, Sullivan-Halley J, Neuhausen SL, Bernstein L.
    • Breast Cancer Res. 2016 Jun 17;18(1):62. doi: 10.1186/s13058-016-0723-3.
    • [BRCA1/2 gene mutation and clinicopathologic features of triple negative breast cancer].
    • Ma ZP, Wang W, Zhang W.
    • Zhonghua Bing Li Xue Za Zhi. 2016 Jun 8;45(6):397-400. doi: 10.3760/cma.j.issn.0529-5807.2016.06.009.
    • [Article in Chinese]
    • Comment on 'Circulating cell-free miRNAs as biomarker for triple-negative breast cancer'-Methodological challenges in combining miRNAs as circulating biomarkers.
    • Verderio P, Bottelli S, Lecchi M, Plebani M, Gariboldi M, Pizzamiglio S, Ciniselli CM.
    • Br J Cancer. 2016 May 10;114(10):e5. doi: 10.1038/bjc.2016.1. Epub 2016 Apr 21.

    Response to: Comment on 'Circulating cell-free miRNAs as biomarker for triple-negative breast cancer'.

    • The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.
    • Anders CK, Abramson V, Tan T, Dent R.
    • Am Soc Clin Oncol Educ Book. 2016 May;(36):34-42. doi: 10.1200/EDBK_159135.
    • The function of MiR-21 expression differences and pathogenesis on familial and triple negative breast Cancer serum.
    • Song N, Liang B, Wang D.
    • Pak J Pharm Sci. 2016 Mar;29(2 Suppl):679-84.
    • Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer.
    • Tung N, Garber JE, Hacker MR, Torous V, Freeman GJ, Poles E, Rodig S, Alexander B, Lee L, Collins LC, Schnitt SJ.
    • NPJ Breast Cancer. 2016 Feb 24;2:16002. doi: 10.1038/npjbcancer.2016.2. eCollection 2016.
    • Family History of Cancer in Relation to Breast Cancer Subtypes in African American Women.
    • Bethea TN, Rosenberg L, Castro-Webb N, Lunetta KL, Sucheston-Campbell LE, Ruiz-Narváez EA, Charlot M, Park SY, Bandera EV, Troester MA, Ambrosone CB, Palmer JR.
    • Cancer Epidemiol Biomarkers Prev. 2016 Feb;25(2):366-73. doi: 10.1158/1055-9965.EPI-15-1068. Epub 2015 Dec 31.
    • The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.
    • Anders CK, Abramson V, Tan T, Dent R.
    • Am Soc Clin Oncol Educ Book. 2016;35:34-42. doi: 10.14694/EDBK_159135.
    • Racial disparities in breast cancer diagnosis and treatment by hormone receptor and HER2 status.
    • Chen L, Li CI.
    • Cancer Epidemiol Biomarkers Prev. 2015 Nov;24(11):1666-72. doi: 10.1158/1055-9965.EPI-15-0293. Epub 2015 Oct 13.
    • Circulating cell-free miRNAs as biomarker for triple-negative breast cancer.
    • Shin VY, Siu JM, Cheuk I, Ng EK, Kwong A.
    • Br J Cancer. 2015 May 26;112(11):1751-9. doi: 10.1038/bjc.2015.143. Epub 2015 Apr 23.
    • Clinical and molecular characteristics of triple-negative breast cancer patients in Northern Israel: single center experience.
    • Asleh-Aburaya K, Fried G.
    • Springerplus. 2015 Mar 15;4:132. doi: 10.1186/s40064-015-0900-3. eCollection 2015.
    • The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: triple-negative breast cancer.
    • Newman LA, Reis-Filho JS, Morrow M, Carey LA, King TA.
    • Ann Surg Oncol. 2015 Mar;22(3):874-82. doi: 10.1245/s10434-014-4279-0. Epub 2014 Dec 20.
    • Review
    • Radiation therapy in the locoregional treatment of triple-negative breast cancer.
    • Moran MS.
    • Lancet Oncol. 2015 Mar;16(3):e113-e122. doi: 10.1016/S1470-2045(14)71104-0.
    • Review
    • Family history of breast and ovarian cancer and triple negative subtype in hispanic/latina women.
    • Anderson K, Thompson PA, Wertheim BC, Martin L, Komenaka IK, Bondy M, Daneri-Navarro A, Meza-Montenegro MM, Gutierrez-Millan LE, Brewster A, Madlensky L, Tobias M, Natarajan L, Martínez ME.
    • Springerplus. 2014 Dec 11;3:727. doi: 10.1186/2193-1801-3-727. eCollection 2014.
    • The Triple-Negative Breast Cancer Database: an omics platform for reference, integration and analysis of triple-negative breast cancer data.
    • Raju R, Paul AM, Asokachandran V, George B, Radhamony L, Vinaykumar M, Girijadevi R, Pillai MR.
    • Breast Cancer Res. 2014 Dec 4;16(6):490. doi: 10.1186/s13058-014-0490-y.
    • TNBC vs non-TNBC: A retrospective review of differences in mean age, family history, smoking history, and stage at diagnosis.
    • Tariq K, Farhangi A, Rana F.
    • Clin Adv Hematol Oncol. 2014 Jun;12(6):377-81.
    • Tackling the diversity of triple-negative breast cancer.
    • Turner NC, Reis-Filho JS.
    • Clin Cancer Res. 2013 Dec 1;19(23):6380-8. doi: 10.1158/1078-0432.CCR-13-0915.
    • Angiogenetic axis angiopoietins/Tie2 and VEGF in familial breast cancer.
    • Danza K, Pilato B, Lacalamita R, Addati T, Giotta F, Bruno A, Paradiso A, Tommasi S.
    • Eur J Hum Genet. 2013 Aug;21(8):824-30. doi: 10.1038/ejhg.2012.273. Epub 2012 Dec 12.
    • BRCA1 polymorphisms and breast cancer epidemiology in the Western New York exposures and breast cancer (WEB) study.
    • Ricks-Santi LJ, Nie J, Marian C, Ochs-Balcom HM, Trevisan M, Edge SB, Freudenheim JL, Shields PG.
    • Genet Epidemiol. 2013 Jul;37(5):504-11. doi: 10.1002/gepi.21730. Epub 2013 May 14.
    • Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy.
    • Xu Y, Diao L, Chen Y, Liu Y, Wang C, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Deng D, Narod SA, Xie Y.
    • Ann Oncol. 2013 Jun;24(6):1498-505. doi: 10.1093/annonc/mdt011. Epub 2013 Feb 13.
    • Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers.
    • Lips EH, Mulder L, Oonk A, van der Kolk LE, Hogervorst FB, Imholz AL, Wesseling J, Rodenhuis S, Nederlof PM.
    • Br J Cancer. 2013 May 28;108(10):2172-7. doi: 10.1038/bjc.2013.144. Epub 2013 Apr 4.
    • [Triple-negative breast cancer: histoclinical and molecular features, therapeutic management and perspectives].
    • Gonçalves A, Sabatier R, Charafe-Jauffret E, Gilabert M, Provansal M, Tarpin C, Extra JM, Viens P, Bertucci F.
    • Bull Cancer. 2013 May;100(5):453-64. doi: 10.1684/bdc.2013.1740.
    • Review, [Article in French]
    • Genetic susceptibility to triple-negative breast cancer.
    • Stevens KN, Vachon CM, Couch FJ.
    • Cancer Res. 2013 Apr 1;73(7):2025-30. doi: 10.1158/0008-5472.CAN-12-1699. Epub 2013 Mar 27.
    • First description of an acinic cell carcinoma of the breast in a BRCA1 mutation carrier: a case report.
    • Ripamonti CB, Colombo M, Mondini P, Siranoush M, Peissel B, Bernard L, Radice P, Carcangiu ML.
    • BMC Cancer. 2013 Feb 1;13:46. doi: 10.1186/1471-2407-13-46.
    • Evaluation of BRCA1 mutations in an unselected patient population with triple-negative breast cancer.
    • Rummel S, Varner E, Shriver CD, Ellsworth RE.
    • Breast Cancer Res Treat. 2013 Jan;137(1):119-25. doi: 10.1007/s10549-012-2348-2. Epub 2012 Nov 29.
    • Genetic susceptibility Loci for subtypes of breast cancer in an african american population.
    • Palmer JR, Ruiz-Narvaez EA, Rotimi CN, Cupples LA, Cozier YC, Adams-Campbell LL, Rosenberg L.
    • Cancer Epidemiol Biomarkers Prev. 2013 Jan;22(1):127-34. doi: 10.1158/1055-9965.EPI-12-0769. Epub 2012 Nov 7.
    • Triple Negative Breast Cancer - An Overview.
    • Aysola K, Desai A, Welch C, Xu J, Qin Y, Reddy V, Matthews R, Owens C, Okoli J, Beech DJ, Piyathilake CJ, Reddy SP, Rao VN.
    • Hereditary Genet. 2013;2013(Suppl 2). pii: 001.
    • Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network.
    • Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, Blayney DW, Niland JC, Winer EP, Weeks JC.
    • Cancer. 2012 Nov 15;118(22):5463-72. doi: 10.1002/cncr.27581. Epub 2012 Apr 27.
    • DNA mismatch repair deficiency in breast carcinoma: a pilot study of triple-negative and non-triple-negative tumors.
    • Wen YH, Brogi E, Zeng Z, Akram M, Catalano J, Paty PB, Norton L, Shia J.
    • Am J Surg Pathol. 2012 Nov;36(11):1700-8. doi: 10.1097/PAS.0b013e3182627787.
    • Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy.
    • Oonk AM, van Rijn C, Smits MM, Mulder L, Laddach N, Savola SP, Wesseling J, Rodenhuis S, Imholz AL, Lips EH.
    • Ann Oncol. 2012 Sep;23(9):2301-5. doi: 10.1093/annonc/mdr621. Epub 2012 Feb 21.

    Free text: Clinical Correlates of 'BRCAness' in Triple-Negative Breast Cancer of Patients Receiving Adjuvant Chemotherapy. (Medscape)

    • Triple-negative breast cancer: epidemiological considerations and recommendations.
    • Boyle P.
    • Ann Oncol. 2012 Aug;23 Suppl 6:vi7-12.
    • Molecular insights on basal-like breast cancer.
    • Valentin MD, da Silva SD, Privat M, Alaoui-Jamali M, Bignon YJ.
    • Breast Cancer Res Treat. 2012 Jul;134(1):21-30. doi: 10.1007/s10549-011-1934-z. Epub 2012 Jan 11.
    • Review
    • Methylation of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients.
    • Fumagalli C, Pruneri G, Possanzini P, Manzotti M, Barile M, Feroce I, Colleoni M, Bonanni B, Maisonneuve P, Radice P, Viale G, Barberis M.
    • Breast Cancer Res Treat. 2012 Jul;134(1):131-7. doi: 10.1007/s10549-011-1945-9. Epub 2012 Jan 8.
    • Triple-negative breast cancer: are we making headway at least?
    • Arnedos M, Bihan C, Delaloge S, Andre F.
    • Ther Adv Med Oncol. 2012 Jul;4(4):195-210. doi: 10.1177/1758834012444711.
    • BRCA2 mutations and triple-negative breast cancer.
    • Meyer P, Landgraf K, Högel B, Eiermann W, Ataseven B.
    • PLoS One. 2012;7(5):e38361. doi: 10.1371/journal.pone.0038361. Epub 2012 May 30.
    • Dissecting the heterogeneity of triple-negative breast cancer.
    • Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA Jr, Ellis P, Di Leo A, Baselga J, Sotiriou C, Piccart-Gebhart M.
    • J Clin Oncol. 2012 May 20;30(15):1879-87. doi: 10.1200/JCO.2011.38.2010. Epub 2012 Mar 26.
    • Review
    • Occurrence of breast cancer subtypes in adolescent and young adult women.
    • Keegan TH, Derouen MC, Press DJ, Kurian AW, Clarke CA.
    • Breast Cancer Res. 2012 Mar 27;14(2):R55.
    • BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years.
    • Robertson L, Hanson H, Seal S, Warren-Perry M, Hughes D, Howell I, Turnbull C, Houlston R, Shanley S, Butler S, Evans DG, Ross G, Eccles D, Tutt A, Rahman N.
    • Br J Cancer. 2012 Mar 13;106(6):1234-8. doi: 10.1038/bjc.2012.31. Epub 2012 Feb 14.

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: NCCN breast guidelines - 2 questions

    Press: Calls for expanded BRCA1 genetic testing of women (PHG Foundation)

    Press: BRCA1 testing for triple-negative breast cancer (Lancet Oncology)

    • Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design.
    • Eiermann W, Bergh J, Cardoso F, Conte P, Crown J, Curtin NJ, Gligorov J, Gusterson B, Joensuu H, Linderholm BK, Martin M, Penault-Llorca F, Pestalozzi BC, Razis E, Sotiriou C, Tjulandin S, Viale G.
    • Breast. 2012 Feb;21(1):20-6. doi: 10.1016/j.breast.2011.09.006. Epub 2011 Oct 8.
    • Review